CodeBlue urges Malaysian MPs to vote for tobacco control bill

Jul.18.2022
CodeBlue urges Malaysian MPs to vote for tobacco control bill
Malaysian health NGO, CodeBlue, urges lawmakers to support the Tobacco and Smoking Control Bill to ban cigarettes for those born after 2005.

CodeBlue, a non-profit health organization in Malaysia, is urging lawmakers to vote in support of the "Tobacco and Smoking Control Bill," which would prohibit individuals born after 2005 from purchasing and using cigarettes. Here is the full statement.


The crucial "Tobacco and Smoking Control Act" will be submitted to Parliament this week, which will have an impact on the health and social welfare of our future generations. It is crucial that all members of Parliament fully understand these issues and support this important legislation.


It is important to note that this bill does not restrict smoking among adults, but rather aims to prohibit the sale and use of cigarettes and e-cigarette products to all children born after 2005 (those who will turn 18 in 2023).


Smoking is a rapidly growing epidemic among our children. The 2019 national health and disease rate survey provides us with national data on adolescent smoking behavior. The data is alarming for children aged 15 to 19, as it shows a significant increase in smoking rates.


At present, there are 303,800 smokers, accounting for 11.6% of the population.


A total of 196,000 individuals, which is equivalent to 7.5% of the population, are currently using e-cigarettes.


15.6% of teenagers aged 15 to 19 are currently using tobacco products.


It is anticipated that since the investigation, there has been a significant increase in the number of adolescents who have started using electronic cigarettes in recent years. As pediatricians, we are aware that many young children are drawn to using electronic cigarette products due to their appealing flavors and stylish devices, as well as the desire to appear "cool".


Teenagers smoking electronic cigarettes and becoming addicted can be seen throughout the country. It is widely recognized that most smokers develop their habit in their teens, and smoking e-cigarettes only makes it easier to develop addiction.


Worrying statistics have emerged from the Malaysian National Tobacco and E-cigarette Survey among Youth (TECMA), which shows that 9.1% of Malaysian youths aged 10 to 19 currently use e-cigarettes, with at least 600,000 children included in this group. Among these children, half started using e-cigarettes before the age of 14.


Smoking addiction is extremely difficult to overcome. Some users will gradually turn to more addictive and harmful drugs.


We urge our congressional representatives to consider the health and well-being of all of our children. Please vote in favor of the Tobacco Control Act. The impact of eliminating a major source of social ills and reducing the long-term health problems and death tolls cannot be overstated.


Voting in favor of this bill is a vote in support of investing in the current and future health and well-being of our children.


Voting in favor of the bill represents a vote of hope for all families whose children are no longer addicted to drugs or e-cigarettes.


Voting in favor of the bill is a vote in support of our healthcare system to alleviate the burden of major illnesses.


Dr. Amar-Singh HSS is a pediatric consultant.


Dr. Selva Kumar is a pediatric consultant and the president of the Malaysian Pediatric Association (MPA).


Dr. Musa Mohd Nordin, pediatric consultant.


Dr. Zulkifli Ismail, Pediatric Consultant.


Dr. Thiyagar Nadarajaw is a pediatric consultant and vice president of the Malaysian Adolescent Health Association (MAAH).


Please provide context and the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26